Free Circulating Tumor DNA as a Diagnostic Marker for Breast Cancer

Journal of Clinical Laboratory Analysis

Volumn 26, Issue 6, 2012, Pages 467-472

  Hashad, D ^a   Sorour, A ^a   Ghazal, A ^a   Talaat, I ^a  

^a ALEXANDRIA UNIVERSITY   (Egypt)

Author keywords

Breast cancer; Cell free plasma DNA; Real time quantitative PCR

Indexed keywords

CELL FREE DNA; DNA; DNA TOPOISOMERASE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; PROGESTERONE RECEPTOR; TUMOR MARKER; UNCLASSIFIED DRUG;

ARTICLE; BREAST CANCER; CIRCULATING TUMOR CELL; CONTROLLED STUDY; DIAGNOSTIC VALUE; FEMALE; HUMAN; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; PLASMA; PROGNOSIS; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION;

ANTIGENS, NEOPLASM; BREAST NEOPLASMS; CASE-CONTROL STUDIES; DNA TOPOISOMERASES, TYPE II; DNA, NEOPLASM; DNA-BINDING PROTEINS; FEMALE; HUMANS; NEOPLASM STAGING; REAL-TIME POLYMERASE CHAIN REACTION; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; TUMOR MARKERS, BIOLOGICAL;

EID: 84869051782     PISSN: 08878013     EISSN: 10982825     Source Type: Journal    
DOI: 10.1002/jcla.21548     Document Type: Article

References (24)

1. Seedhom A, Kamal N. Factors affecting survival of women diagnosed with breast cancer in El-Minia governorate. Egypt Int J Prev Med 2011;2:131-138.
2. Agarwal G, Ramakant P, Forgach E, et al. Breast cancer care in developing countries. World J Surg 2009;33:2069-2076.
3. Pantel K, Muller V, Auer M, et al. Detection and clinical implications of early systemic tumour cell dissemination in breast cancer. Clin Cancer Res 2003;9:6326-6334.
4. Diel I, Solomayer E, Bastert G. Bisphosphonates and the prevention of metastasis: First evidences from preclinical and clinical studies. Cancer 2000;88:3080-3088.
5. Kuzhan O, Ozet A, Ulutin C, et al. Impact of c-erb2 status on survival after high dose chemotherapy in high-risk breastcancer patients. Saudi Med J 2007;28:1374-1379.
6. Hannemann J, Kristel P, van Tinteren H, et al. Molecular subtypes of breast cancer and amplification of Topoisomerase IIa: Predictive role in dose intensive adjuvant chemotherapy. Br J Cancer 2006;95:1334-1341.
7. Leon S, Shapiro B, Sklaroff D, et al. Free DNA in the serum of cancer patients and the effect of therapy. Cancer Res 1977;37:646-650.
8. Gautschi O, Bigosch C, Huegli B, et al. Circulating deoxyribonucleic acid as prognostic marker in non-small-cell lung cancer patients undergoing chemotherapy. J Clin Oncol 2004;22:4157-4164.
9. Jahr S, Hentze H, Englisch S, et al. DNA fragments in the blood plasma of cancer patients: Quantitations and evidence for their origin from apoptotic and necrotic cells. Cancer Res 2001;61:1659-1665.
10. Gormally E, Caboux E, Vineis P, Hainaut P. Circulating free DNA in plasma or serum as biomarker of carcinogenesis: Practical aspects and biological significance. Mut Res 2007;635:105-117.
11. Edge SB, Byrd DR, Compton CC, Fritz AG, Greene FL, Trotti A, editors. American Joint Committee on Cancer Staging Manual, seventh edition, New York: Springer; 2010.
12. Tavassoli F, Devilee P. World Health Organization Classification of Tumours: Tumors of the Breast and Female Genital Organs. Lyon: IARC Press, International Agency for Research on Cancer; 2003. p 18-19.
13. Catarino R, Ferreira M, Rodrigues H, et al. Quantification of free circulating tumor DNA as a diagnostic marker for breast cancer. DNA Cell Biol 2008;27:415-420.
14. Onitilo A, Engel J, Greenlee R, Mukesh B. Breast cancer subtypes based on ER/PR and Her2 expression: Comparison of clinicopathologic features and survival. Clin Med Res 2009;7:4-13.
15. Collins LC, Botero ML, Schnitt SJ. Bimodal frequency distribution of EstrogenReceptor immunohistochemical staining results in breast cancer. Am J ClinPathol 2005;123:16-20.
16. Wolff AC, Hammond ME, Schwartz JN, et al. American Society of Clinical Oncology; College of American Pathologists. American Society of Clinical Oncology/College of American Pathologists Guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. Arch Path Lab Med 2007;131:18-43.
17. Yasojima H, Shimmura A, Naoi Y, et al. Association between c-myc amplification and pathological complete response to neoadjuvant chemotherapy in breast cancer. Association between c-myc amplification and pathological complete response to neoadjuvant chemotherapy in breast cancer. Eur J Cancer 2011;47:1779-1788.
18. Sandri M, Hochhauser D, Ayton P, et al. Differential expression of the Topoisomerase II alpha and beta genes in human breast cancers. Br J Cancer 1996;73:1518-1524.
19. Kohler C, Radpour R, Barekati Z, et al. Levels of plasma circulating cell free nuclear and mitochondrial DNA as potential biomarkers for breast tumors. Mol Cancer 2009;8:105-113.
20. Catarino R, Ferreira M, Rodrigues H, et al. Quantification of free circulating tumor DNA as a diagnostic marker for breast cancer. DNA Cell Biol 2008;27:415-421.
21. Shao ZM, Wu J, Shen ZZ, Nguyen M. p53 mutationin plasma DNA and its prognostic value in breast cancer patients. Clin Cancer Res 2001;7: 2222-2227.
22. Zhong X, Ladewig A, Schmid S, et al. Elevated level of cell-free plasma DNA is associated with breast cancer. Arch Gynecol Obstet 2007;276:327-331.
23. Eccles S. The role of c-erbB-2/HER2/NEU/neu in breast cancer progression and metastasis. J Mammary Gland Biol Neoplasia 2002;6:393-406.
24. Berger JM, Gamblin SJ, Harrison SC, et al. Structure and mechanism of DNA topoisomerase IIα. Nature 1996;379:225-232.